The US Centers for Disease Control and Prevention and the US Food and Drug Administration said they had lifted their recommend pause on use of Johnson & Johnson’s coronavirus vaccine Friday.
The agencies recommended the pause April 13 after learning of six cases of a rare blood clotting syndrome among women who had recently received the vaccine.
Earlier Friday, the CDC’s Advisory Committee on Immunization Practices recommended lifting the pause.
“During the pause, medical and scientific teams at the FDA and CDC examined available data to assess the risk of thrombosis involving the cerebral venous sinuses, or CVST (large blood vessels in the brain), and other sites in the body (including but not limited to the large blood vessels of the abdomen and the veins of the legs) along with thrombocytopenia, or low blood platelet counts,” the agencies said in a joint statement. “The teams at FDA and CDC also conducted extensive outreach to providers and clinicians to ensure they were made aware of the potential for these adverse events and could properly manage and recognize these events due to the unique treatment required for these blood clots and low platelets, also known as thrombosis-thrombocytopenia syndrome (TTS).”
The CDC said it now has collected reports of 15 such cases, all in women and 13 of them in women under 50.